Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Study of Deucravacitinib in Japanese Subjects with Moderate-to-Severe Psoriasis
jRCT2080224603Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deucravacitinib in plaque psoriasis, psoriatic arthritis (PsA), erythrodermic psoriasis (EP) and 1 more, sponsored by Bristol Myers Squibb. Started Mar 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)erythrodermic psoriasis (EP)generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2080224603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224603.